Mizuho Raises Boston Scientific (BSX) Price Target as Robotics and Devices Drive Growth

Boston Scientific Corporation (NYSE:BSX) ranks among the top robotics to buy according to analysts. Mizuho kept its Outperform rating on Boston Scientific Corporation (NYSE:BSX), and increased its price target for the medical device maker from $130 to $140 on July 24.

The firm reported that the global recall of the ACURATE transcatheter aortic valve replacement (TAVR) system in the second half of the year was expected to be compensated by solid performance in Boston Scientific’s FARAPULSE and WATCHMAN product lines.

While Boston Scientific Corporation (NYSE:BSX) has no plans to re-engineer the ACURATE valve, putting it “at square one in the TAVR space,” the company is still on track to acquire clearances for FARAPULSE in China and Japan before the end of the year, according to Mizuho’s research.

Boston Scientific Corporation (NYSE:BSX) is a global leader in the manufacture of medical devices, including stents, brain stimulation systems, heart monitors, and catheters. A leading name in robotics, the company has made great strides in the humanoid aspect of the industry with its two-legged Atlas robot.

While we acknowledge the potential of BSX to grow, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than BSX and that has 100x upside potential, check out our report about this cheapest AI stock.

READ NEXT: 10 Best Magic Formula Stocks for 2025 and 10 Best Retirement Stocks to Buy According to Hedge Funds.

Disclosure: None. This article is originally published at Insider Monkey.